TheraRadar
Data updated: May 26, 2026

SERNIVO (betamethasone dipropionate)

Dermatology Approved 2016-02-05

SERNIVO is indicated for the treatment of Dermatoses.

Source: FDA Label • PRIMUS PHARMS

How SERNIVO Works

Betamethasone dipropionate is a corticosteroid that influences cellular signaling, immune function, and protein regulation. While the exact mechanism of action in the treatment of plaque psoriasis is not fully established, it is recognized for its anti-inflammatory, antipruritic, and vasoconstrictive properties.

1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2016-02-05
Patent Cliff
2030

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
SPRAY

Companies

Active Ingredient: BETAMETHASONE DIPROPIONATE

SERNIVO Approval History

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2016 to 2020
Mar 2020 SUPPL
Label · Labeling
Nov 2018 SUPPL
Label · Labeling
Feb 2016 ORIGINAL
New Form · Type 3 - New Dosage Form

What SERNIVO Treats

1 indications

SERNIVO is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dermatoses
Source: FDA Label

SERNIVO Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to SERNIVO

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALA-SCALP
HYDROCORTISONE
1 shared
LEGACY PHARMA
Shared indications:
ALCLOMETASONE DIPROPIONATE
ALCLOMETASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
AMCINONIDE
AMCINONIDE
1 shared
TARO PHARM INDS
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT03999229 STUDY20221492 5R01HL126900 Ph 1 recruiting S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
NCT06332612 MROSF 8420224AROM Ph 1, Ph 2 completed Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SERNIVO FDA Label Details

Indications & Usage

FDA Label (PDF)

SERNIVO is indicated for the treatment of Dermatoses.

View full patent landscape →
7 OB patents · 1 families · 33 international docs across 6 countries

SERNIVO Patents & Exclusivity

Latest Patent: Aug 2030

Patents (7 active)

US9775851 Expires Aug 31, 2030
US9364485 Expires Aug 31, 2030
US9655907 Expires Aug 31, 2030
US10179137 Expires Aug 31, 2030
US9433630 Expires Aug 31, 2030
US9877974 Expires Aug 31, 2030
US9439911 Expires Aug 31, 2030
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for SERNIVO

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2030
  • 7 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.